INAB

IN8bio, Inc. Common Stock

2.01

USD

INAB Earnings Reports

Positive Surprise Ratio

INAB beat 10 of 17 last estimates.

59%

Next Report

Date of Next Report

Mar 02, 2026

Estimate for Q4 25 (Revenue/ EPS)

-$0.52

Implied change from Q3 25 (Revenue/ EPS)

-38.82%

Implied change from Q4 24 (Revenue/ EPS)

-56.67%

IN8bio, Inc. Common Stock earnings per share and revenue

On Nov 06, 2025, INAB reported earnings of -0.85 USD per share (EPS) for Q3 25, beating the estimate of -1.25 USD, resulting in a 32.25% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -6.63% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 4 analysts forecast an EPS of -0.52 USD, with revenue projected to reach -- USD, implying an decrease of -38.82% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Nurix Therapeutics, Inc. Common stock

Report Date

Jan 28, 2026 For Q4 25

Estimate

-$0.88

Actual

-$0.82

Surprise

+7.66%

FAQ

What were IN8bio, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, IN8bio, Inc. Common Stock reported EPS of -$0.85, beating estimates by 32.25%, and revenue of $0.00, 0% as expectations.

How did the market react to IN8bio, Inc. Common Stock's Q3 2025 earnings?

The stock price moved down -6.63%, changed from $1.66 before the earnings release to $1.55 the day after.

When is IN8bio, Inc. Common Stock expected to report next?

The next earning report is scheduled for Mar 02, 2026.

What are the forecasts for IN8bio, Inc. Common Stock's next earnings report?

Based on 4 analysts, IN8bio, Inc. Common Stock is expected to report EPS of -$0.52 and revenue of -- for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.